Instruments to Account for Higher Market Share
By capturing nearly 3/4 share of total market value, instruments continue to lead the pack, with their share exhibiting an increasing trend through 2029. Under the component type, immunofluorescence slide scanners will remain highly preferred over other instruments such as multispectral imaging systems and toponome imaging systems.
Benefits such as high image quality, reliability, and speed for entire slide imaging are influencing the inclination of manufacturers towards these instrument. Further, quantitative pathology imaging systems, although in their nascent stage, are also echoing potential sales prospects for market players.
Focus Sustained on Developed Regional Markets
Accounting for a collective share of 80%, North America and Western Europe will remain the key contributors to the revenue of the global multiplex biomarker imaging market. These developed regions continue to reflect lucrative growth potential due to supportive government policies and increasing financial assistance for laboratory and clinical research.
Being early adopters of innovative technologies and advanced healthcare infrastructure, market players are dedicating a significant slice of their investments to these regions. Given the emergence of cutting-edge technologies and rising per capita healthcare spending in Asia Pacific (APAC), the multiplex biomarker imaging market in this region is also receiving an impetus.
Coupling Multispectral Imaging with Multiplexing for Broadened Application Scope
Multispectral imaging is gaining good reputation within the biomedical sphere, as it optimizes the multiplexing process and curbs the side effects of auto-fluorescence in sync. This could further serve several purposes, including identifying target protein expression, detection of exact tumor location, oxy-deoxy hemoglobin status, and documentation of drug delivery. Leading market players are leveraging this imaging technique by increasing the component ion base of multispectral imaging devices that could provide multiplexing biomarker imaging, which, in turn, would help reap bigger margins.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
How Growth will Unfold
Considering efficiency in terms of processing time and accuracy during identification of target proteins in tissue samples, immunohistochemistry (IHC) assays will continue to stay at the forefront throughout the forecast period. This study reveals that, the adoption of this imaging technique will achieve its peak in 2022, registering revenue worth US$ 300 Mn. While IHC assay remain the focus of various immuno-oncology research, fluorescence in situ hybridization (FISH) and transcription-mediated amplification (TMA) assays are also finding immense utilization in molecular diagnostics applications.
FREQUENTLY ASKED QUESTIONS ABOUT MULTIPLEX BIOMARKER IMAGING MARKET
What is the current and future market status of multiplex biomarker imaging?
The global multiplex biomarker imaging market is anticipated to experience robust growth in the foreseeable future, and is expected to expand nearly 3X its current market value by the end of 2029.
Which trend is prominent that favors the growth of the multiplex biomarker imaging market?
Over the last few years, there has been greater demand for advanced methods for offering functional evidence on cellular protein components of cancerous tissues. Additionally, tech developments for better diagnosis and management of various oncological disorders are anticipated to bolster the demand for multiplex biomarker imaging techniques.
Where does major opportunity lie?
Demand is primarily emerging from developing countries such as China and India for cancer research, especially non-small cell lung cancer (NSCLC), for improved stratification of patients and faster diagnosis. Better accessibility to advanced healthcare and diagnostic infrastructure, as well as the establishment of translational laboratories are factors contributing to the growing number of multiplex biomarker imaging methods.
Which players are identified as tier-1 players in the multiplex biomarker imaging market?
PerkinElmer, Bio-Rad, and Thermo Fisher Scientific are some of key players in the multiplex biomarker imaging market that FMI has recognized as tier-1 players. Most of these players are focusing on expansion through strategic acquisition of regional players to maintain their market position in the multiplex biomarker imaging market.
Which end-use industry offers high potential opportunities for market players?
Translational laboratories are anticipated to represent a significant market share in the multiplex biomarker imaging market, and remain the most lucrative segment throughout the forecast period, as they deliver high-quality R&D services involving cancer biomarkers.
MULTIPLEX BIOMARKER IMAGING MARKET TAXONOMY
The global multiplex biomarker imaging market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to readers.
- Quantitative Pathology Imaging Systems
- Immunofluorescence Slide Scanners
- Toponome Imaging Systems
- Multispectral Imaging Systems
- Installation & Integration Services
- Maintenance Services
- Immunohistochemistry (IHC) Assays
- Fluorescent In-Situ Hybridization (FISH) Assays
- Tissue Microarray (TMA) Assays
- Clinical Diagnostics
- Translation Laboratories
- Biopharmaceutical Companies
- Academic Institutes
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan (APEJ)
- Middle East and Africa